Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis

Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer

(2012) Shivangi Trivedi et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine

(2012) Hannelouise Kissow et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice

(2012) Hannelouise Kissow et al.   REGULATORY PEPTIDES

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual  -Cell Function

(2011) U. Kielgast et al.   DIABETES

Palifermin Reduces Severe Mucositis in Definitive Chemoradiotherapy of Locally Advanced Head and Neck Cancer: A Randomized, Placebo-Controlled Study

(2011) Quynh-Thu Le et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum levels of NF-κB and pro-inflammatory cytokines following administration of mucotoxic drugs

(2010) Richard M Logan et al.   CANCER BIOLOGY & THERAPY

The Intestinotrophic Peptide, GLP-2, Counteracts the Gastrointestinal Atrophy in Mice Induced by the Epidermal Growth Factor Receptor Inhibitor, Erlotinib, and Cisplatin

(2010) Andreas Rosén Rasmussen et al.   DIGESTIVE DISEASES AND SCIENCES

Glucagon-Like Peptide-1 Protects  -Cells Against Apoptosis by Increasing the Activity of an Igf-2/Igf-1 Receptor Autocrine Loop

(2009) M. Cornu et al.   DIABETES

Carcinogenic Effects of Exogenous and Endogenous Glucagon-Like Peptide-2 in Azoxymethane-Treated Mice

(2009) Roman Iakoubov et al.   ENDOCRINOLOGY

Insulin-like growth factor I and glucagon-like peptide-2 responses to fasting followed by controlled or ad libitum refeeding in rats

(2008) David W. Nelson et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Emerging drugs for chemotherapy-induced mucositis

(2008) Dorothy M Keefe et al.   EXPERT OPINION ON EMERGING DRUGS